Publications
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Xiao W, Miles LA, Bowman RL, Durani V, Tian HS, DelGaudio NL, Mishra T, Zhu M, Zhang Y, Stump SE, Tallman MS, Levine RL, Cai SF
Blood AdvancesDec 2020
Abstract
Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.